Merck, CLL12225YR-1VL, Safe Harbor Landing Pad Cell Line HCT-116 Cancer Cells

General description
The STR profile of this cell line matches that of its parental cell line ATCC® Catalog No. CCL-247. HCT-116 cancer cells are a human colorectal carcinoma cell line isolated from the colon of an adult male. The cells possess a near diploid karyotype and express carcinoembryonic antigen.
Application
This product is a human HCT-116 carcinoma cell line in which a landing pad cassette has been integrated into the AAVS1 safe harbor locus using CompoZr® Zinc Finger Nuclease technology. The mKATE2 fluorescence gene was integrated following the EF1a promoter and flanked by unique Cre-lox sites. The design of this landing pad cassette allows for easy, fast, and affordable genetic modification using Cre recombinase. mKATE2 can easily be exchanged for a payload of the user′s choice using Cre recombinase and a targeting vector with appropriate lox sites. Cells can then be sorted via fluorescence-activated cell sorting (FACS) for loss of mKATE2 expression as a surrogate for successful integration of the targeting vector. Approximately 7-10 days are required for loss of the mKATE2 signal in successfully targeted cells. See technical bulletin for detailed protocols.
Biochem/physiol Actions
These cells are a human colorectal carcinoma cell line isolated from the colon of an adult male. The cells possess a near diploid karyotype and express carcinoembryonic antigen.
Features and Benefits
These cells contain the mKATE2 fluorescence gene flanked by unique Cre-lox sites inserted in the AAVS1 safe harbor gene. These HCT-116 cells are adherent with a doubling time of approximately 22 hours.
Preparation Note
McCoy′s 5A medium modified to contain 1.5mM L-glutamine and 2200mg/L sodium bicarbonate. Add 10% FBS.
Analysis Note
Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, short terminal repeat (STR) analysis for cell line identification.
Legal Information
ATCC is a registered trademark of American Type Culture Collection
CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany